Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biomerica (BMRA) Gross Margin (2016 - 2025)

Biomerica's Gross Margin history spans 16 years, with the latest figure at 4.38% for Q4 2025.

  • For Q4 2025, Gross Margin fell 2233.0% year-over-year to 4.38%; the TTM value through Nov 2025 reached 5.59%, down 512.0%, while the annual FY2025 figure was 9.38%, 191.0% down from the prior year.
  • Gross Margin for Q4 2025 was 4.38% at Biomerica, down from 30.72% in the prior quarter.
  • Across five years, Gross Margin topped out at 35.52% in Q2 2021 and bottomed at 32.98% in Q2 2025.
  • The 5-year median for Gross Margin is 11.26% (2022), against an average of 9.44%.
  • The largest annual shift saw Gross Margin skyrocketed 2741bps in 2023 before it plummeted -3477bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 16.61% in 2021, then skyrocketed by 43bps to 23.74% in 2022, then fell by -13bps to 20.74% in 2023, then increased by 29bps to 26.71% in 2024, then tumbled by -84bps to 4.38% in 2025.
  • Per Business Quant, the three most recent readings for BMRA's Gross Margin are 4.38% (Q4 2025), 30.72% (Q3 2025), and 32.98% (Q2 2025).